Form 4 for SEPN Septerna, Inc.
Accepted 2025-11-13 00:00:00 ET · period of report 2025-11-10 · accession 0001193125-25-280756 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-13 | 2025-11-10 | SEPN | Long Daniel D. | SVP, Drug Discovery | S - Sale | $18.06 | -3,501 | 92.9K | -4% | -$63.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-10 | S | D | 3,501 | $18.06 | 92,911 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.04 to $18.16. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. (F2) Includes 3,501 shares acquired under the Septerna, Inc. 2024 Employee Stock Purchase Plan on October 31, 2025 in transactions that were exempt under Rule 16b-3(c). |